AML is an aggressive blood cancer in which abnormal myeloid cells accumulate in the bone marrow and interfere with the production of normal blood cells. Mutations in the gene encoding FLT3, a receptor tyrosine kinase that transmits growth and survival signals, are among the most common genetic alterations found in AML. These mutations can cause FLT3 to remain abnormally active, encouraging leukemia cells to multiply rapidly and resist normal controls on growth. Several drugs, including gilteritinib, have been developed to block mutant FLT3, but patients frequently experience treatment resistance or relapse.

“FLT3 mutations are one of the most common genetic drivers of AML,” said corresponding author Dr. Daisuke Nakada, Henry and Emma Meyer Professor in Molecular and Human Genetics at Baylor College of Medicine. Earlier work had established that FLT3 inhibition can stop leukemia cells from dividing and activate apoptosis, a programmed self-destruction pathway. Nakada and his colleagues investigated whether the drugs might also kill AML cells through a mechanism that does not depend solely on apoptosis. Their experiments revealed that the answer is ferroptosis, a distinct process that is increasingly recognized as an important vulnerability in cancer.

Ferroptosis occurs when cells lose the ability to control lipid peroxidation. In this process, reactive oxygen molecules attack polyunsaturated fatty acids within cellular membranes, generating unstable lipid compounds that damage membrane structure and disrupt essential cellular functions. Unlike apoptosis, which involves an organized dismantling of the cell, ferroptosis is associated with catastrophic oxidative injury. The researchers observed evidence of this process in mouse models, laboratory leukemia cell lines and patient-derived AML samples transplanted into animals, demonstrating that the mechanism was not restricted to a single experimental system.

The team traced the vulnerability to GPX4, an enzyme that protects cell membranes from lipid peroxidation. GPX4 is a selenoprotein, meaning that it contains the trace element selenium as part of its active structure. By reducing harmful lipid peroxides, GPX4 acts as one of the cell’s most important defenses against ferroptosis. The researchers found that mutant FLT3 supports the production of GPX4 and other selenoproteins in AML cells. When FLT3 is blocked, this production is disrupted, leaving leukemia cells increasingly exposed to oxidative damage.

According to the study, the effect is not simply a matter of FLT3 inhibitors switching off a growth signal. The drugs also appear to interfere with the cellular machinery required to make selenoproteins. As GPX4 levels fall, AML cells become less capable of neutralizing lipid peroxides. The resulting accumulation of oxidized lipids pushes the cells beyond a critical threshold, triggering ferroptotic death. This connection between mutant FLT3 signaling, selenium-dependent protein production and ferroptosis provides a biochemical explanation for why FLT3-mutant leukemia may be particularly sensitive to the treatment.

Analysis of samples from AML patients offered additional clues about resistance. Leukemia samples that had become resistant to gilteritinib frequently showed increased activity in genes involved in selenoprotein production. The pattern suggests that resistant cells may survive by strengthening the very protective pathway that FLT3 inhibitors weaken. By increasing their capacity to synthesize GPX4 and related proteins, the cells could restore their ability to control lipid peroxidation even while FLT3 signaling remains suppressed. This observation raises the possibility that the selenoprotein pathway could serve as a biomarker of resistance or a target for combination therapies.

The researchers also identified a potential influence outside the cancer cell itself: dietary vitamin E. Vitamin E is an antioxidant that can limit lipid oxidation, and experiments showed that dietary supplementation markedly reduced the effectiveness of gilteritinib in animal models. The result does not establish that ordinary dietary intake compromises treatment, nor does it provide a basis for patients to change supplements without medical advice. It does, however, highlight the importance of understanding how antioxidants may affect therapies that depend on oxidative damage to eliminate cancer cells. High-dose vitamin E supplementation could theoretically suppress the ferroptotic mechanism activated by FLT3 inhibition.

The findings position ferroptosis as a possible therapeutic lever in FLT3-mutant AML and suggest several avenues for future research. Drugs that further weaken GPX4 activity, disrupt selenium metabolism or increase lipid peroxidation might enhance the effects of FLT3 inhibitors, particularly in resistant disease. At the same time, any such approach would require careful dosing because ferroptosis-related processes also occur in normal tissues. The study was conducted by scientists from Baylor College of Medicine, the University of Texas MD Anderson Cancer Center, Texas A&M University and Washington University School of Medicine, with support from federal, philanthropic and Texas-based research programs. Further clinical studies will be needed to determine whether manipulating ferroptosis can improve outcomes for people with AML.

Subject of Research: FLT3-mutant acute myeloid leukemia, ferroptosis and resistance to FLT3 inhibitors.

News Publication Date: Aug. 7, 2026.

Web References: Nature Cell Biology; https://doi.org/10.1038/s41556-026-02016-5

References: DOI: 10.1038/s41556-026-02016-5.

Keywords: acute myeloid leukemia, AML, FLT3, FLT3 inhibitors, gilteritinib, ferroptosis, GPX4, selenoproteins, lipid peroxidation, cancer therapy, drug resistance, vitamin E, leukemia research

CoQ10, a lipophilic molecule embedded within the inner mitochondrial membrane, functions fundamentally as an electron carrier in the mitochondrial respiratory chain. However, emerging evidence positions CoQ10 oxidoreductases as critical modulators of redox balance, influencing a cell’s propensity to undergo ferroptosis. Ferroptosis is characterized by iron-driven accumulation of lipid-based reactive oxygen species (ROS), disrupting cellular membranes and leading to an oxidative demise distinct from apoptosis or necrosis. This pathway has garnered attention for its potential to selectively target cancer cells resistant to conventional apoptosis-inducing therapies.

The research team deciphers how CoQ10 oxidoreductases exert a finely-tuned redox regulation, effectively governing ferroptotic sensitivity. These enzymes catalyze the reduction of CoQ10, sustaining its antioxidant capacity to mitigate lipid peroxidation. Intriguingly, certain cancers exhibit dysregulated expression or activity of these oxidoreductases, skewing the redox balance and fostering resistance against ferroptotic triggers. This mechanistic insight deepens our understanding of how cancer cells adapt to oxidative stress, potentially exploiting CoQ10 pathways to evade death.

A central revelation from the study is how CoQ10 oxidoreductase activity functions not only as a metabolic safeguard but also as a regulatory nexus controlling lipid peroxide detoxification. By reducing CoQ10, these enzymes replenish ubiquinol pools—powerful chain-breaking antioxidants that inhibit the propagation of lipid radicals in membranes. This antioxidative shield forms a biochemical barrier against ferroptotic induction, supporting cancer cell survival amid fluctuating oxidative milieus.

Ferroptosis has emerged as a compelling alternative to traditional apoptosis-centered therapies, particularly in malignancies exhibiting refractory resistance or mutated apoptotic machinery. The modulation of CoQ10 oxidoreductases, therefore, uncovers a therapeutic opportunity to sensitize tumors to ferroptotic death. Pharmacological inhibition or genetic suppression of these enzymes could dismantle the antioxidative defenses, augmenting lipid peroxidation and tipping the scales toward ferroptosis. Such strategies may offer a precision oncology approach, exploiting metabolic vulnerabilities while sparing normal tissues.

Adding complexity, the study highlights the context-dependent roles of different CoQ10 oxidoreductases isoforms across various cancer types. Some enzymes are upregulated, conferring enhanced ferroptosis resistance, whereas others might paradoxically promote oxidative stress under specific metabolic states. This heterogeneity accentuates the necessity for tailored therapeutic designs considering tumor-specific redox landscapes and CoQ10 enzymatic profiles.

Moreover, the researchers explore the cross-talk between CoQ10 oxidoreductases and other ferroptosis regulators, such as glutathione peroxidase 4 (GPX4) and membrane lipid remodeling enzymes. Inhibitory effects on CoQ10 oxidoreductases synergize with GPX4-targeting agents, generating combinatorial lethality that dismantles both lipid peroxide scavenging and detoxification pathways. This dual targeting could overcome resistance mechanisms and potentiate ferroptotic responses in challenging cancer subtypes.

Beyond its anti-ferroptotic functions, CoQ10 reduction by these oxidoreductases indirectly influences mitochondrial bioenergetics and ROS generation, highlighting an intricate feedback loop intertwining metabolic flux and redox signaling. As cancer cells often rewire mitochondrial dynamics to fuel aggressive phenotypes, manipulating CoQ10 oxidoreductase activity could disrupt cellular energetics, further sensitizing tumors to ferroptotic death.

The therapeutic implications of these findings are manifold. Small molecules modulating CoQ10 oxidoreductase activity offer a promising class of anticancer agents. Currently, several inhibitors are in preclinical evaluation, aiming to destabilize ubiquinol regeneration and collapse cellular redox defenses. Nanotechnology-enhanced delivery systems engineered to target tumors could also enhance drug specificity, reducing off-target effects and oxidative toxicity to healthy tissues.

Translationally, the elucidation of CoQ10 oxidoreductases as ferroptosis gatekeepers may provide prognostic biomarkers for patient stratification. Expression levels or enzymatic activity profiles could predict tumor susceptibility to ferroptosis-inducing therapies, enabling more personalized treatment regimens. Additionally, monitoring redox metabolites derived from CoQ10 pathways may serve as dynamic markers of therapeutic response.

Despite these advances, challenges remain in fully deciphering the intricate regulation of ferroptosis by CoQ10 oxidoreductases. Tumor microenvironment factors such as hypoxia, nutrient availability, and iron metabolism intricately modulate ferroptotic outcomes and CoQ10 enzyme function. Future studies must integrate multi-omic and spatial profiling to map these interactions comprehensively, paving the way for sophisticated intervention strategies.

In conclusion, the pioneering work of Lee and colleagues spotlights CoQ10 oxidoreductases as critical arbiters of ferroptotic cell death in cancer, functioning through redox regulation of lipid peroxide detoxification and cellular bioenergetics. Their dual role in shielding tumor cells and offering a therapeutic Achilles’ heel heralds a new chapter in redox biology and cancer therapy. As ferroptosis-based interventions advance toward clinical reality, targeting CoQ10 oxidoreductases emerges as a promising strategy to overcome drug resistance and improve patient outcomes in the relentless battle against cancer.

The implications of these findings extend beyond oncology, potentially informing therapeutic approaches for other diseases characterized by dysregulated redox homeostasis and lipid peroxidation, including neurodegeneration and cardiovascular disorders. The nuanced understanding of CoQ10 oxidoreductase function thus heralds broader biomedical significance, representing a cornerstone of future redox medicine.

Subject of Research:
CoQ10 oxidoreductases in ferroptosis regulation and cancer therapy

Article Title:
CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities.

Article References:
Lee, J., Yoo, I., Kim, M. et al. CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01736-w

Image Credits: AI Generated

DOI: 03 June 2026